Drug Abuse Screening Test

Abbreviation
DAST
Description

A brief instrument for clinical and non-clinical screening to detect drug abuse or dependence disorders. It is most useful in settings in which seeking treatment for drug use problems is not the patient's stated goal. The DAST provides a quantitative index of the severity of problems related to drug abuse other than alcohol.

Category
Substance Use
Subcategory
Drugs

Breath Alcohol

Abbreviation
EXH-Alc
Description

Expired alcohol level, used to estimate the blood alcohol concentration (BAC)

Category
Substance Use
Subcategory
Alcohol

Perceived Stress Scale

Abbreviation
PSS
Description

A 14-item scale for measuring the degree to which situations in one’s life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. The scale also includes a number of direct queries about current levels of experienced stress. Moreover, the questions are of a general nature and hence are relatively free of content specific to any sub-population group.

Category
Mental Health
Subcategory
Anxiety

Questionnaire of Smoking Urges

Abbreviation
QSU
Description

A 32-item scale designed to measure cravings elicited by abstinence from cigarette smoking. Items in the scale were generated to represent four theoretically and clinically distinct conceptualizations of smoking urges: (1) desire to smoke, (2) anticipation of positive outcomes from smoking, (3) anticipation of relief from nicotine withdrawal or from withdrawal-associated negative affect, and (4) intention to smoke.

Category
Substance Use
Subcategory
Tobacco

Minnesota Tobacco Withdrawal Scale

Abbreviation
MTWS
Description

A self-report scale and an observer scale for examining the severity of nicotine withdrawal symptoms in a subject. Both scales rate the severity of four symptoms related to nicotine withdrawal: "angry/irritable/frustrated," "anxious/tense," "depressed," and "restless/impatient." The self-report scale adds several others that cannot be observed by outsiders.

Category
Substance Use
Subcategory
Tobacco
Division
HEAL Study
Title
Double-Blind, Placebo-Controlled, Dose Response Trial Of Ondansetron For The Treatment Of Methamphetamine Dependence
Short Description
This study was designed to be a preliminary assessment of the efficacy and safety of 3-wide range doses of ondansetron (0.25, 1.0 and 4.0 mg taken orally twice per day) to reduce methamphetamine use in subjects with methamphetamine dependence and to determine the optimal dose of ondansetron.
Release Date
Jan 15, 2019
Description

The primary objective of this study is to conduct a preliminary assessment of the possible efficacy of ondansetron to reduce methamphetamine use in outpatients with methamphetamine dependence. The hypothesis is that ondansetron treatment compared to placebo will decrease the weekly proportion of methamphetamine positive urines. The results of this study will be used to design subsequent larger studies to confirm the efficacy of ondansetron. This study is also intended to gather preliminary information on biological or psychosocial characteristics of patients who may show better ondansetron treatment responsiveness.

Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
Study Links
Study Documents
Dictionary
Case Report Form(s)
Deidentification Notes